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Congenital Melanocytic Nevi Frequently Harbor
NRAS Mutations but no BRAF Mutations
Ju¨rgen Bauer1,2, John A. Curtin3, Dan Pinkel3 and Boris C. Bastian1,3,4
Most melanocytic nevi develop on sun-exposed skin during childhood and adolescence and commonly harbor
BRAF mutations or, less frequently, NRAS mutations. A small subset of nevi is present at birth, and therefore
must develop independently of UV light. To assess whether these nevi have a different mutation spectrum than
those that develop on sun-exposed skin, we determined the BRAF and NRAS mutation frequencies in 32 truly
congenital nevi. We found no BRAF mutations, but 81% (26/32) harbored mutations in NRAS. Consistently, seven
of 10 (70%) proliferating nodules that developed early in life in congenital nevi showed mutations in NRAS.
A separate set of nevi that displayed histological features frequently found in nevi present at birth (‘‘congenital
pattern nevi’’) but lacked a definitive history of presence at birth showed an inverse mutation pattern with
common BRAF mutations (20/28 or 71%) and less frequent NRAS mutations (7/28 or 25%). Thus, nevi that
develop in utero are genetically distinct from those that develop later, and histopathologic criteria alone are
unable to reliably distinguish the two groups. The results are consistent with the finding in melanoma that BRAF
mutations are uncommon in neoplasms that develop in the absence of sun-exposure.
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INTRODUCTION
Activating mutations within the kinase domain of the BRAF
gene are a common somatic event in melanoma (Davies
et al., 2002) as well as in benign melanocytic nevi (Pollock
et al., 2003). Whereas sunlight is an undisputed etiological
factor in the development of melanoma (Gandini et al., 2005)
and nevi (Bauer et al., 2005), the role of UV exposure in the
formation of BRAF mutations is unclear. About 90% of BRAF
mutations found in melanoma and melanocytic nevi result
in T-to-A transversions at nucleotide 1796 and therefore lack
the typical UV radiation signature of CC-to-TT or C-to-T
transitions. In melanoma, the finding of frequent BRAF
mutations in tumors on intermittently sun-exposed skin, and
the infrequent BRAF mutations in melanomas on relatively or
completely sun-protected body sites (Maldonado et al., 2003;
Cohen et al., 2004; Edwards et al., 2004; Sasaki et al., 2004;
Wong et al., 2005) suggest a link, possibly indirect, between
exposure to UV light and the induction of BRAF mutations.
However, the lack of BRAF mutations in melanomas on skin
that has received high levels of sun exposure and their
frequent occurrence in histologically defined congenital nevi
(Pollock et al., 2003; Yazdi et al., 2003) argue against a
causative link between UV light and BRAF mutations in
melanocytic neoplasia.
Strictly defined, congenital melanocytic nevi are nevi that
are present at birth and thus have developed in utero in the
absence of UV exposure. However, less stringent definitions
are commonly used by the medical field, for example, nevi
that arise in the first years of life are often termed ‘‘tardive’’
congenital nevi, and pathologists commonly make the
diagnosis of a congenital nevus in young adults and adults
based on the presence of particular histopathologic features
that are found in nevi that are truly congenital. If these criteria
are inadequate to recognize nevi that developed in utero,
then some of the implications drawn from previous studies of
BRAF mutation frequencies in nevi may be in error. In this
study, we compare the mutation frequencies of BRAF and
NRAS in 32 melanocytic nevi that definitively developed
in utero, in 10 proliferating nodules that developed in such
congenital nevi, and in 28 melanocytic nevi excised later in
life and showing only histopathologic features similar to
congenital nevi, the so-called ‘‘congenital pattern nevi’’. We
demonstrate that these groups of nevi are very distinct in their
mutation spectrum. Our results have important clinical
implications, as congenital nevi are considered precursors
of melanoma with estimated lifetime risks ranging from 5 to
40% (Tannous et al., 2005).
RESULTS AND DISCUSSION
None of the 32 melanocytic nevi that were present at birth
nor any of the 10 nodular proliferations that developed in
melanocytic nevi present at birth showed BRAF mutations. In
contrast, 20 of 28 (71%) of the melanocytic nevi with a
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‘‘congenital pattern’’ showed the common BRAF V600E
mutation. Mutation analysis of NRAS in the cases that were
wild type for BRAF revealed an inverse distribution: 26 of the
32 nevi present at birth (81%) and seven of the 10 (70%)
proliferating nodules showed mutations in NRAS (Tables 1
and 2). Previous studies on truly congenital nevi also found
frequent NRAS mutations in codon 61 (Carr and Mackie,
1994) and no BRAF mutations (Papp et al., 1999; De Raeve
et al., 2006). Only seven of 28 (25%) nevi with a ‘‘congenital
pattern’’ showed NRAS mutations. These nevi may thus
represent ‘‘true’’ congenital nevi in which NRAS mutations
developed in utero, or acquired nevi in which the mutations
developed later in life.
These results are in striking contrast to earlier studies that
have reported BRAF mutations in six out of seven (85.7%)
(Pollock et al., 2003) or in six out of 13 (46.2 %) melanocytic
nevi that were classified as congenital (Yazdi et al., 2003).
Several explanations for this discrepancy are possible. We
could have missed BRAF mutations in nevi present at birth
because of normal cell contamination or because our patients
were young, and mutations could still develop later in life
in such nevi. Both possibilities are highly unlikely because
(i) nevi present at birth showed contiguous areas of melano-
cytes that could be easily dissected away from normal tissue,
and (ii) we found frequent activating mutations in NRAS,
which are virtually never found when the BRAF V600E
mutation is present (Davies et al., 2002), making it very
unlikely that BRAF mutations were missed or arose later in
progression of these nevi.
We believe that the difference between our mutation
analysis and previous results is based on the fact that the
classification of nevi as congenital in the previous studies was
based on histological criteria, not actual presence at birth.
Nevi present at birth frequently show distinctive microscopic
features including splaying of nevus cells between collagen
bundles in the lower two-thirds of the reticular dermis, within
hair follicles, eccrine ducts, or blood vessel walls (Mark et al.,
1973). These criteria are commonly used to classify nevi
whose age of appearance is unknown as ‘‘congenital pattern
nevi’’. These are sometimes assumed to be truly congenital.
However, several studies have shown that these histopatho-
logic features are not specific to nevi present at birth. In one
study, nevi that were not present at examination at birth but
occurred in the first 3 years of life showed a congenital
pattern in 47% of the cases (Clemmensen and Kroon, 1988).
Two other studies compared melanocytic nevi in children
based on clinical files or parents’ information as to whether a
nevus was acquired or congenital. These studies concluded
that the histopathologic features had limited specificity as
predictor of presence at birth (Rhodes et al., 1985; Cribier
et al., 1999).
The nevi present at birth in our study were at least several
centimeters in diameter, qualifying as medium to large size
congenital nevi by conventional criteria (Kopf et al., 1979),
whereas the nevi with a ‘‘congenital pattern’’ were signifi-
cantly smaller with a maximum diameter of 13 mm. Reliable
histories regarding presence at birth of small nevi are difficult
to obtain and were not available for the group of ‘‘congenital
pattern’’ nevi in our study. This group is thus expected to
contain a mixture of nevi acquired after birth and nevi present
at birth. Because a subset of nevi in the ‘‘congenital pattern’’
group also contained NRAS mutations that were common in
the group of nevi present at birth, it is possible that these also
developed before birth. Alternatively, it is conceivable that
the marked differences in the mutation frequencies of
BRAF and NRAS do not apply for small nevi that developed
before birth, indicating genetic differences between truly
congenital nevi that are small and those that are large. Such
differences would thus be independent of environmental
factors such as UV light and depend more likely on the
developmental stage of the organism or melanocyte at which
the mutations occur. Some studies have found a relatively
high risk of progression to melanoma for small histologically
defined congenital nevi (Rhodes and Melski, 1982; Rhodes
et al., 1982). Therefore, an improved understanding of
the mutation spectrum in nevi of all sizes that are present at
birth, ‘‘tardive’’ congenital nevi that develop during the first
year of life, and histologically defined congenital nevi may
allow more sophisticated partitioning of progression risk
among the nevus subtypes and substantially improve patient
management.
The high frequency of NRAS mutations in nevi that
developed in utero demonstrates that UV light is not required
Table 1. Clinical characteristics of tumors and patients
Congenital
melanocytic nevi
Proliferating nodules in
congenital melanocytic nevi
Congenital
pattern nevi
n (samples) 32 10 28
Male/female 14/18 2/7 9/13
Age range (median) 1 day to 30 years (1.3 years) 2–135 days (40 days) 15–67 years (40 years)
Table 2. Frequencies of BRAF and NRAS mutations
Congenital
melanocytic
nevi
Proliferating
nodules in congenital
melanocytic nevi
Congenital
pattern nevi
BRAF mutations 0 (0%) 0 (0%) 20 (71.4%)
NRAS mutations 26 (81.3%) 7 (70.0%) 7 (25.0%)
No mutations 6 (18.8%) 3 (30.0%) 1 (3.6%)
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for NRAS mutations. In contrast, the complete absence of
BRAF mutations in nevi present at birth, but their frequent
occurrence in acquired nevi, parallels the finding in
melanoma in which BRAF mutations are found in melanomas
that occur on intermittently sun-exposed body sites but are
rare to absent in melanomas developing in completely sun-
protected mucosa-lined body cavities (Cohen et al., 2004;
Edwards et al., 2004; Sasaki et al., 2004; Wong et al., 2005).
These striking patterns suggest a possible link between UV
exposure and BRAF mutations in melanocytic neoplasia.
However, any connection is likely to be complex as the
mutations also occur in other cancers and do not show
typical signatures of UV induction (Davies et al., 2002).
Any link between BRAF mutations and UV light is further
complicated by the fact that melanomas arising on skin areas
with the highest UV exposure rarely have BRAF mutations
(Maldonado et al., 2003). We therefore proposed that UV
exposure might be an important causative factor for the
formation of BRAF mutations in melanocytic tumors, but is
not sufficient. Recent molecular (Curtin et al., 2005) and
epidemiologic (Whiteman et al., 2003) studies have led us to
suggest that a hypothesis that integrates these results. We
have proposed that there are genetically distinct types of
melanomas with regard to their mutation spectrum, and that
individuals have a genetically determined susceptibility to
UV exposure that strongly influences the genetic characteris-
tics of a melanoma that they may develop. The hypo-
thesized susceptibility operates either through a higher
probability of melanocytes to acquire BRAF mutations if
exposed to UV or to proliferate if such a mutation occurs. The
present study extends these observations and the hypothesis
to the development of nevi. Thus, we propose that truly
congenital nevi, none of which have BRAF mutations, may be
found on both (or either) susceptible and resistant individuals.
Acquired nevi, most of which have BRAF mutations (Pollock
et al., 2003; Yazdi et al., 2003), and melanomas with BRAF
mutations occur in the more susceptible individuals and
require modest UV exposure for their formation. Resistant
individuals do not develop melanomas until they have had
high total UV exposures, and these melanomas predomi-
nantly do not have BRAF mutations. Further study is required
to determine the validity of this susceptibility hypothesis, and
to define its genetic basis. However, until a formal proof of
this hypothesis can be rendered, other mechanisms explain-
ing the higher prevalence of BRAF mutations in sun-exposed
sites have to be considered.
In summary, our data show that nevi that develop in utero,
in the absence of UV exposure, are genetically distinct from
nevi developing after birth, even those that have histological
similarities with truly congenital nevi. Our findings are
consistent with the observation in melanoma that BRAF
mutations are rare in neoplasms developing in UV-protected
sites suggesting a connection, whether direct or indirect,
between BRAF mutations and UV exposure. Better under-
standing of the genetic differences among histologically
similar nevi with overlapping histological appearances may
substantially improve the ability to make clinical decisions
concerning the risk of progression to melanoma.
MATERIALS AND METHODS
We selected 32 melanocytic nevi from the archives of the
Department of Pathology of the University of California, San
Francisco, in which there was a documented history that the nevus
was present at birth. The study was approved by the Institutional
Review Board of the University of California, San Francisco. The
patient ages ranged from 1 day to 30 years (median 16 months,
Table 1 and Table S1). The DNA was extracted from micro-dissected
paraffin sections and BRAF exon 15 was amplified as published
previously (Maldonado et al., 2003). For all tumors in which no
mutations were found in exon 15, we also sequenced NRAS codon
61. PCR products were purified using ExoSAP-IT (USB Corporation,
Cleveland, OH) and sequenced directly using an ABI PRISM 3700
DNA Analyzer (Applied Biosystems, Foster City, CA). In addition, we
sequenced 10 atypical nodular cellular proliferations of a separate
set of patients with melanocytic nevi present at birth. Atypical
nodular proliferations typically present as rapidly growing tumors
that develop shortly after birth and can simulate melanoma clinically
and histopathologically. For comparison, we retrieved 28 melano-
cytic nevi from 22 patients that showed histopathologic features
similar to congenital nevi (‘‘congenital pattern nevi’’) as defined by
the presence of melanocytes clustered in the vicinity of adnexal
structures, vessels or nerves, or splayed between the collagen
bundles of the reticular dermis (Mark et al., 1973). No information
was available as to whether these nevi were present at birth. The
median age of this group of patients was 40 and the age ranged from
15 to 67 years.
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